Statistics for Adaptimmune Therapeutics Plc (id:8224 ADAP)

Valuation metrics

Market cap

152.25M

Enterprise value

739.74M

Trailing P/E (ttm)

-1.23

Forward P/E

-1.57

PEG ratio

-1.57

Price/Sales (ttm)

1.08

Price/Book (mrq)

3.42

Enterprise Value/Revenue

5.23

Enterprise Value/EBITDA

-10.15

Overview

Shares outstanding

255.88M

Float

1.02B

Shares short

5.35M

% Held by insiders

0.00%

% Held by institutions

0.60%

Average volume (10 days)

2.69M

Average volume (90 days)

Price summary

52-Week low

0.42

52-Week high

2.05

52-Week change

30.08%

Beta

2.25

50-Day moving average

0.88

200-Day moving average

1.13

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

March 30th, 2018

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-51.25%

Operating margin

53.58%

Operational effectiveness

Return on assets

-15.84%

Return on equity

-65.04%

Income statement

Revenue (ttm)

0.60

Revenue per share (ttm)

0.60

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-72,880,000.00

Net income to common (ttm)

-72,500,000.00

Diluted EPS (ttm)

-0.17

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

214.79M

Total cash per share (mrq)

0.14

Total debt (mrq)

47.35M

Total Debt/Equity (mrq)

49.18

Current ratio (mrq)

309.20%

Book value per share (mrq)

0.17

Cash flow

Cash flow statement

-44,386,000.00

Levered free cash flow (LFCF)

-7,946,125.00